A review of a family of ultra-rapid-acting insulins: Formulation development

Journal of Diabetes Science and Technology

Volumn 6, Issue 4, 2012, Pages 786-796

  Krasner, Alan ^a   Pohl, Roderike ^a   Simms, Patrick ^a   Pichotta, Philip ^a   Hauser, Robert ^a   De Souza, Errol ^a  

^a Biodel Inc   (United States)

Author keywords

Insulin monomers; Insulin therapy; Linjeta; Prandial insulin; Ultra rapid insulin

Indexed keywords

BIOD 090; BIOD 100; BIOD 105; BIOD 107; BIOD 123; BIOD 125; BIOD 200; BIOD 300; BIOD 400; CALCIUM; CALCIUM CHLORIDE; CITRIC ACID; EDETIC ACID; EXCIPIENT; GLUCOSE; HEMOGLOBIN A1C; HUMAN INSULIN; INSULIN; INSULIN DERIVATIVE; INSULIN GLULISINE; INSULIN LISPRO; LINJETA; MAGNESIUM SULFATE; MONOMER; PIG INSULIN; RECOMBINANT HUMAN INSULIN; SHORT ACTING INSULIN; ULTRA RAPID ACTING INSULIN; UNCLASSIFIED DRUG; VIAJECT; ZINC; ANTIDIABETIC AGENT; DRUG DERIVATIVE;

CHELATION; CONFERENCE PAPER; DIABETES MELLITUS; DOSE RESPONSE; DRUG ABSORPTION; DRUG FORMULATION; EXPERIMENTAL MODEL; GLUCOSE BLOOD LEVEL; HUMAN; INJECTION SITE PAIN; INJECTION SITE REACTION; INSULIN DEPENDENT DIABETES MELLITUS; MEAL; MULTIPLE DRUG DOSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTPRANDIAL STATE; REPRODUCIBILITY; SURFACE CHARGE; ANIMAL; CHEMISTRY; CLINICAL TRIAL (TOPIC); DRUG DESIGN; EVALUATION; METHODOLOGY; REVIEW; STATISTICS; SYNTHESIS;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS; DRUG DESIGN; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN, SHORT-ACTING;

EID: 84873191592     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/193229681200600408     Document Type: Conference Paper

References (17)

1. Brange J, Langkjoer L. Insulin structure and stability. Pharm Biotechnol. 1993;5:315-50.
2. Pohl R, Hauser R, Li M, DeSouza E, Feldstein R, Seibert R, Ozhan K, Kashyap N, Steiner S. Ultra-rapid absorption of recombinant human insulin induced by zinc chelation and surface charge masking. J Diabetes Sci Technol. 2012;6(4):755-63.
3. Steiner S, Hompesch M, Pohl R, Simms P, Flacke F, Mohr T, Pfützner A, Heinemann L. A novel insulin formulation with a more rapid onset of action. Diabetologia. 2008;51(9):1602-6. Epub 2008 Jul 19.
4. Heinemann L, Hompesch M, Flacke F, Simms P, Pohl R, Albus K, Pfützner A, Steiner S. Reduction of postprandial glycemic excursions in patients with type 1 diabetes: a novel human insulin formulation versus a rapid-acting insulin analog and regular human insulin. J Diabetes Sci Technol. 2011;5(3):681-6.
5. Hompesch M, McManus L, Pohl R, Simms P, Pfützner A, Bülow E, Flacke F, Heinemann L, Steiner SS. Intra-individual variability of the metabolic effect of a novel rapid-acting insulin (VIAject) in comparison to regular human insulin. J Diabetes Sci Technol. 2008;2(4):568-71.
6. Forst T, Pfützner A, Flacke F, Krasner A, Hohberg C, Tarakci E, Pichotta P, Forst S, Steiner S. Postprandial vascular effects of VIAject compared with insulin lispro and regular human insulin in patients with type 2 diabetes. Diabetes Care. 2010;33(1):116-20. Epub 2009 Oct 6.
7. Hollander P, Flacke F, Simms P, Krasner A, Pichotta P, Pfützner A, Steiner, S. An Open-Label, Multicenter Trial of VIAject® vs. Regular Human Insulin in Patients with Type 1 Diabetes: Impact of Regional Differences on Efficacy Analyses. Presented at: 2010 ADA 70th Annual Scientific Sessions, Orlando, FL, June 25-29, 2010.
8. Rodbard HW, Flacke F, Simms P, Krasner A, Pichotta P, Pfützner A, Steiner S. An Open-Label Multicenter Trial of VIAject® vs. Regular Human Insulin in Patients with Type 2 Diabetes: Final Analyses. Presented at: 2010 ADA 70th Annual Scientific Sessions, Orlando, FL, June 25-29, 2010.
9. Hollander P, Flacke F, Simms P, Pichotta P, Steiner S, Krasner A. Assessment of Long-Term Safety and Efficacy of Linjeta™ with 18 Months of Continuous Therapy in Patients with Type 1 Diabetes. Presented at: 2011 ADA 71st Annual Scientific Sessions, San Diego, CA, June 24-28, 2011.
10. Rodbard HW, Flacke F, Simms P, Pichotta P, Steiner S, Krasner A. Assessment of Long-Term Safety and Efficacy of Linjeta™ with 18 Months of Continuous Therapy in Patients with Type 2 Diabetes. Presented at: 2011 ADA 71st Annual Scientific Sessions, San Diego, CA, June 24-28, 2011.
11. Heinemann L, Nosek L, Flacke F, Albus K, Krasner A, Pichotta P, Heise T, Steiner S. U-100, pH-Neutral formulation of VIAject®: faster onset of action than insulin lispro in patients with type 1 diabetes. Diabetes Obes Metab. 2012;14(3):222-7. doi: 10.1111/j.1463-1326.2011.01516.x. Epub 2011 Nov 13.
12. Hubbard JI, Jones SF, Landau EM. On the mechanism by which calcium and magnesium affect the release of transmitter by nerve impulses. J Physiol. 1968;196(1):75-86.
13. Flacke F, Blanchfield L, Hem-Lee H, Pichotta P, Krasner A, Steiner S. Characterization of Pharmacokinetics adn Toleration of Three Variant Formulations of Linjeta(TM). Presented at: Diabetes Technology Meeting, Bethesda, MD, November 11-13, 2010.
14. Stevens RA, Urmey WF, Urquhart BL, Kao TC. Back pain after epidural anesthesia with chloroprocaine. Anesthesiology. 1993;78(3):492-7. (Pubitemid 23090484)
15. Lee C, Song YK, Jeong HM, Park SN. The effects of magnesium sulfate infiltration on perioperative opioid consumption and opioid-induced hyperalgesia in patients undergoing robot-assisted laparoscopic prostatectomy with remifentanil-based anesthesia. Korean J Anesthesiol. 2011;61(3):244-50. Epub 2011 Sep 23.
16. Ushida T, Iwatsu O, Shimo K, Tetsunaga T, Ikeuchi M, Ikemoto T, Arai YC, Suetomi K, Nishihara M. Intradermal administration of magnesium sulphate and magnesium chloride produces hypesthesia to mechanical but hyperalgesia to heat stimuli in humans. J Neuroinflammation. 2009;6:25.
17. Feria M,Abad F, Sánchez A, Abreu P. Magnesium sulphate injected subcutaneously suppresses autotomy in peripherally deafferented rats. Pain. 1993;53(3):287-93. (Pubitemid 23172377)